Nektar Therapeutics
NKTR- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000906709
In the last 90 days, Nektar Therapeutics insiders filed 0 open-market purchases and 3 sales; 239 institutions reported holding it in 13F filings for Q2 2026, worth $2.50B in total; no superinvestor holds it.
13F holders, Q2 2023
Institutional positions in Nektar Therapeutics as of Jun 30, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 148
- −49 vs. Q1 2023
- Shares held
- 137.9M
- −34.8M (−20.2%) vs. Q1 2023
- Total value
- $79.3M
- −$41.8M (−34.5%) vs. Q1 2023
- New holders
- 25
- 27 more added
- Sold out
- 74
- 49 more reduced
Compare with Q1 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting NKTR on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 239 | $2.50B |
| Q1 2026 | 216 | $1.94B |
| Q4 2025 | 180 | $732.2M |
| Q3 2025 | 153 | $820.2M |
| Q2 2025 | 109 | $197.7M |
| Q1 2025 | 157 | $84.2M |
| Q4 2024 | 146 | $123.6M |
| Q3 2024 | 140 | $182.9M |
| Q2 2024 | 135 | $168.0M |
| Q1 2024 | 123 | $105.5M |
| Q4 2023 | 127 | $67.3M |
| Q3 2023 | 139 | $85.3M |
| Q2 2023 | 148 | $79.3M |
| Q1 2023 | 197 | $121.2M |
| Q4 2022 | 217 | $381.7M |
| Q3 2022 | 232 | $561.4M |
| Q2 2022 | 230 | $693.8M |
| Q1 2022 | 243 | $947.6M |
| Q4 2021 | 242 | $2.35B |
| Q3 2021 | 243 | $3.01B |
| Q2 2021 | 243 | $2.89B |
| Q1 2021 | 239 | $3.40B |
Institutions, Q2 2023
Shares, value and share of portfolio for each institution holding Nektar Therapeutics; share changes are against Q1 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Handelsbanken Fonder AB | 0 | $0 | 0.00% | −13,934−100.0% | Sold out |
| Coldstream Capital Management Inc | 0 | $0 | 0.00% | −14,161−100.0% | Sold out |
| Pathstone Family Office, LLC | 0 | $0 | 0.00% | −14,161−100.0% | Sold out |
| Ameritas Investment Partners, Inc. | 0 | $0 | 0.00% | −13,610−100.0% | Sold out |
| X-Square Capital, LLC | 0 | $0 | 0.00% | −13,000−100.0% | Sold out |
| Mackenzie Financial Corp | 0 | $0 | 0.00% | −11,940−100.0% | Sold out |
| Profund Advisors LLC | 0 | $0 | 0.00% | −11,912−100.0% | Sold out |
| Shelton Capital Management | 0 | $0 | 0.00% | −11,864−100.0% | Sold out |
| Flagship Harbor Advisors, LLC | 0 | $0 | 0.00% | −10,550−100.0% | Sold out |
| Xponance, Inc. | 0 | $0 | 0.00% | −10,341−100.0% | Sold out |
| Metropolitan Life Insurance Co | 0 | $0 | 0.00% | −10,005−100.0% | Sold out |
| Baader Bank INC | 0 | $0 | 0.00% | −10,723−100.0% | Sold out |
| Belpointe Asset Management LLC | 0 | $0 | 0.00% | −5,495−100.0% | Sold out |
| Baillie Gifford & Co | 0 | $0 | 0.00% | −1,376−100.0% | Sold out |
| Red Tortoise LLC | 0 | $0 | 0.00% | −942−100.0% | Sold out |
| Dark Forest Capital Management LP | 0 | $0 | 0.00% | −429−100.0% | Sold out |
| Baystate Wealth Management LLC | 0 | $0 | 0.00% | −100−100.0% | Sold out |
| Delos Wealth Advisors, LLC | 0 | $0 | 0.00% | −99−100.0% | Sold out |
| Raffa Wealth Management, LLC | 0 | $0 | 0.00% | −33−100.0% | Sold out |
| Advisory Services Network, LLC | 0 | $0 | 0.00% | −3−100.0% | Sold out |
| Toronto Dominion Bank | 0 | $0 | 0.00% | −9−100.0% | Sold out |
| Ronald Blue Trust, Inc. | 0 | $0 | 0.00% | −65−100.0% | Sold out |